TY - JOUR
T1 - Endoscopic full-thickness resection of T1 colorectal cancers
T2 - a retrospective analysis from a multicenter Dutch eFTR registry
AU - Zwager, Liselotte W.
AU - Bastiaansen, Barbara A. J.
AU - van der Spek, Bas W.
AU - Heine, Dimitri N.
AU - Schreuder, Ramon M.
AU - Perk, Lars E.
AU - Weusten, Bas L. A. M.
AU - Boonstra, Jurjen J.
AU - van der Sluis, Hedwig
AU - Wolters, Hugo J.
AU - Bekkering, Frank C.
AU - Rietdijk, Svend T.
AU - Schwartz, Matthijs P.
AU - Nagengast, Wouter B.
AU - ten Hove, W. Rogier
AU - Terhaar sive Droste, Jochim S.
AU - Rando Munoz, Francisco J.
AU - Vlug, Marije S.
AU - Beaumont, Hanneke
AU - Houben, Martin H. M. G.
AU - Seerden, Tom C. J.
AU - de Wijkerslooth, Thomas R.
AU - Gielisse, Eric A. R.
AU - Hazewinkel, Yark
AU - de Ridder, Rogier
AU - Straathof, Jan-Willem A.
AU - van der Vlugt, Manon
AU - Dutch eFTR Group
AU - Koens, Lianne
AU - Fockens, Paul
AU - Dekker, Evelien
N1 - Funding Information: Prof. dr. Fockens reports personal fees from Cook, Ethicon and Olympus, research support from Boston Scientific, outside the submitted work. Prof. dr. Dekker has endoscopic equipment on loan of FujiFilm, received a research grant from FujiFilm, received a honorarium for consultancy from FujiFilm, Olympus, Tillots, GI Supply and CPP-FAP and a speakers' fee from Olympus, Roche and GI Supply. Prof. dr. Weusten received research support from Pentax Medical Inc and Aqua Medical, outside the submitted work. Dr. Bastiaansen received a speakers’ fee from Olympus, Tillotts Pharma AG and Ovesco Endoscopy AG. All other authors have nothing to disclose. Publisher Copyright: © 2021. Thieme. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background: Complete endoscopic resection and accurate histological evaluation for T1 colorectal cancer (CRC) are critical in determining subsequent treatment. Endoscopic full-thickness resection (eFTR) is a new treatment option for T1 CRC<2cm. We aimed to report clinical outcomes and short-term results. Methods: Consecutive eFTR procedures for T1 CRC, prospectively recorded in our national registry between November 2015 and April 2020, were retrospectively analyzed. Primary outcomes were technical success and R0 resection. Secondary outcomes were histological risk assessment, curative resection, adverse events, and short-term outcomes. Results: We included 330 procedures: 132 primary resections and 198 secondary scar resections after incomplete T1 CRC resection. Overall technical success, R0 resection, and curative resection rates were 87.0% (95% confidence interval [CI] 82.7%-90.3%), 85.6% (95%CI 81.2%-89.2%), and 60.3% (95%CI 54.7%-65.7%). Curative resection rate was 23.7% (95%CI 15.9%-33.6%) for primary resection of T1 CRC and 60.8% (95%CI 50.4%-70.4%) after excluding deep submucosal invasion as a risk factor. Risk stratification was possible in 99.3%. The severe adverse event rate was 2.2%. Additional oncological surgery was performed in 49/320 (15.3%), with residual cancer in 11/49 (22.4%). Endoscopic follow-up was available in 200/242 (82.6%), with a median of 4 months and residual cancer in 1 (0.5%) following an incomplete resection. Conclusions: eFTR is relatively safe and effective for resection of small T1 CRC, both as primary and secondary treatment. eFTR can expand endoscopic treatment options for T1 CRC and could help to reduce surgical overtreatment. Future studies should focus on long-term outcomes.
AB - Background: Complete endoscopic resection and accurate histological evaluation for T1 colorectal cancer (CRC) are critical in determining subsequent treatment. Endoscopic full-thickness resection (eFTR) is a new treatment option for T1 CRC<2cm. We aimed to report clinical outcomes and short-term results. Methods: Consecutive eFTR procedures for T1 CRC, prospectively recorded in our national registry between November 2015 and April 2020, were retrospectively analyzed. Primary outcomes were technical success and R0 resection. Secondary outcomes were histological risk assessment, curative resection, adverse events, and short-term outcomes. Results: We included 330 procedures: 132 primary resections and 198 secondary scar resections after incomplete T1 CRC resection. Overall technical success, R0 resection, and curative resection rates were 87.0% (95% confidence interval [CI] 82.7%-90.3%), 85.6% (95%CI 81.2%-89.2%), and 60.3% (95%CI 54.7%-65.7%). Curative resection rate was 23.7% (95%CI 15.9%-33.6%) for primary resection of T1 CRC and 60.8% (95%CI 50.4%-70.4%) after excluding deep submucosal invasion as a risk factor. Risk stratification was possible in 99.3%. The severe adverse event rate was 2.2%. Additional oncological surgery was performed in 49/320 (15.3%), with residual cancer in 11/49 (22.4%). Endoscopic follow-up was available in 200/242 (82.6%), with a median of 4 months and residual cancer in 1 (0.5%) following an incomplete resection. Conclusions: eFTR is relatively safe and effective for resection of small T1 CRC, both as primary and secondary treatment. eFTR can expand endoscopic treatment options for T1 CRC and could help to reduce surgical overtreatment. Future studies should focus on long-term outcomes.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123279905&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/34488228
UR - http://www.scopus.com/inward/record.url?scp=85123279905&partnerID=8YFLogxK
U2 - https://doi.org/10.1055/a-1637-9051
DO - https://doi.org/10.1055/a-1637-9051
M3 - Article
C2 - 34488228
SN - 0013-726X
VL - 54
SP - 475
EP - 485
JO - Endoscopy
JF - Endoscopy
IS - 5
ER -